(Q40386036)

20 September 2017

title

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial (English)

1 reference

20 September 2017

main subject

phase I clinical trial

0 references

leukemia

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

Azra Raza

1

1 reference

20 September 2017

Joseph G Jurcic

2

1 reference

20 September 2017

Gail J Roboz

3

1 reference

20 September 2017

Michael Maris

4

1 reference

20 September 2017

Joseph J Stephenson

5

1 reference

20 September 2017

Brent L Wood

6

1 reference

20 September 2017

Eric J Feldman

7

1 reference

20 September 2017

Naomi Galili

8

1 reference

20 September 2017

Laurie E Grove

9

1 reference

20 September 2017

Jonathan G Drachman

10

1 reference

20 September 2017

Eric L Sievers

11

1 reference

20 September 2017

publication date

1 August 2009

1 reference

20 September 2017

1 reference

20 September 2017

volume

50

1 reference

20 September 2017

issue

8

1 reference

20 September 2017

page(s)

1336-1344

1 reference

Heterogeneity of clonogenic cells in acute myeloblastic leukemia

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903050013

10.1080/10428190903050013

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference